Navigation Links
TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
Date:11/25/2008

LA JOLLA, Calif., Nov. 25 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has purchased from Eli Lilly & Company a reduction in certain royalty amounts that may become payable to Eli Lilly on net sales of TorreyPines' clinical-stage compounds NGX426 and tezampanel, should either or both gain regulatory approval. Specifically, the top tier royalty rate will be reduced three percentage points and the middle tier royalty rate will be reduced one half percentage point. The bottom tier royalty rate will remain unchanged. In addition, certain milestone payments due to Eli Lilly related to the clinical development of NGX426 will be delayed from what was originally agreed. In exchange for the royalty rate reduction and change in milestone payment timing, TorreyPines issued to Eli Lilly two hundred thousand shares of TorreyPines Common Stock at fair market value. TorreyPines originally licensed NGX426 and tezampanel from Eli Lilly in April 2003.

"This agreement with Eli Lilly is another important part of our 2008 strategic plan to strengthen the company and build stockholder value," said Ev Graham, Chief Executive Officer of TorreyPines. "We believe the royalty rate reduction and delay in certain clinical milestone payments for NGX426 will further enhance the commercial value of NGX426 and tezampanel."

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognit
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
2. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
3. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
4. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
5. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
6. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
7. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
8. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
9. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
10. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
11. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , ... PTBI, PTBIW), a biopharmaceutical company advancing patient care in ... offering of 3,500,000 shares of common stock, and warrants ... common stock, at an offering price of $4.00 per ... per share exercise price of $5.00, are exercisable immediately, ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this ... James L. Sherley, director of the Adult Stem Cell ... an often overlooked and under appreciated unique property of ... by Distributed Stem Cells: Misunderstood in the Past, Important ... to congress participants. He gave the address at ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3
... Mass., March 31 Boston Scientific,Corporation (NYSE: ... Scientific Santa,Rosa Corp., formerly known as TriVascular, Inc., ... in Santa Rosa, California. Boston Scientific,Santa Rosa Corp. ... endovascular aortic repair (EVAR) program. Terms of the ...
... ... Year-over-Year, ALISO VIEJO, Calif., ... and services resource for,pathologists, oncologists and the pharmaceutical industry, today announced,financial ... from continuing operations was $12.4 million for the fourth quarter,of 2007, ...
... poster ... presentations, SOUTH SAN FRANCISCO, Calif., March ... clinical,trials of the company,s investigational compounds XL647, XL184, XL765 and,XL880 will be ... will be held from May 30 to June 3, 2008 in,Chicago, Illinois. ...
Cached Biology Technology:Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 2Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 3Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 2Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 3Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 4Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 5Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 6Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 7Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 8Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 9Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting 2
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... RIVERSIDE, Calif. Julia Bailey-Serres , a geneticist whose ... will give a free, public lecture at UC Riverside on ... challenge of improving crop yield in the face of climate ... Solutions," the hour-long lecture will begin at 7 p.m. in ...
... This press release is available in Spanish . ... calves has been developed by Agricultural Research Service (ARS) scientists who ... nutrient the young animals need to promote optimal growth and health. ... from their mothers as they nurse during the first few days ...
... discovered a defect in cellular pathways that provides a new ... newborns, known as craniosynostosis. Mutations of the WNT ... that regulate bone formation at the stem cell level, according ... Science Signaling . "Our work contributes to the ...
Cached Biology News:Public lecture to explore solutions to the food challenge 2Public lecture to explore solutions to the food challenge 3Model developed for manipulating vitamin D levels in calves 2Stem-cell disruption induces skull deformity, UR study shows 2
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: